NCT03698994: Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03698994
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAF, RAS, GNA, MAPK, NF1/2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Patient must have enrolled on the Pediatric MATCH Screening Trial (NCT03155620)
Exclusions: Patients over the age of 21; Patients who have received prior exposure to BVD-523FB (ulixertinib) or other ERK inhibitors
https://ClinicalTrials.gov/show/NCT03698994

Comments are closed.

Up ↑